FY2026 Earnings Estimate for TWST Issued By William Blair

Twist Bioscience Co. (NASDAQ:TWST) – Equities researchers at William Blair issued their FY2026 earnings per share (EPS) estimates for Twist Bioscience in a research note issued to investors on Monday, November 18th. William Blair analyst M. Larew forecasts that the company will earn ($1.50) per share for the year. The consensus estimate for Twist Bioscience’s current full-year earnings is ($3.13) per share.

Several other equities analysts have also commented on TWST. Evercore ISI increased their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Barclays decreased their price objective on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating for the company in a research note on Tuesday. Leerink Partners upped their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a research note on Thursday, October 17th. Robert W. Baird upped their price objective on shares of Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, JPMorgan Chase & Co. upped their price objective on shares of Twist Bioscience from $28.00 to $35.00 and gave the company an “underweight” rating in a research note on Monday, August 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average price target of $51.78.

Twist Bioscience Price Performance

NASDAQ:TWST opened at $41.32 on Wednesday. The firm has a market capitalization of $2.42 billion, a PE ratio of -10.82 and a beta of 1.78. The business’s fifty day moving average price is $43.99 and its 200 day moving average price is $46.18. Twist Bioscience has a 12 month low of $23.00 and a 12 month high of $60.90.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its stake in shares of Twist Bioscience by 1.9% during the 3rd quarter. Geode Capital Management LLC now owns 1,367,759 shares of the company’s stock worth $61,807,000 after purchasing an additional 26,145 shares in the last quarter. Barclays PLC increased its stake in shares of Twist Bioscience by 214.8% during the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock worth $6,913,000 after purchasing an additional 104,420 shares in the last quarter. XTX Topco Ltd increased its stake in shares of Twist Bioscience by 36.7% during the 3rd quarter. XTX Topco Ltd now owns 15,518 shares of the company’s stock worth $701,000 after purchasing an additional 4,169 shares in the last quarter. Wellington Management Group LLP increased its stake in shares of Twist Bioscience by 188.5% during the 3rd quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after purchasing an additional 521,272 shares in the last quarter. Finally, State Street Corp increased its stake in shares of Twist Bioscience by 19.9% during the 3rd quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares in the last quarter.

Insider Buying and Selling

In other Twist Bioscience news, insider Dennis Cho sold 1,507 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $48.00, for a total value of $72,336.00. Following the completion of the transaction, the insider now directly owns 91,163 shares of the company’s stock, valued at approximately $4,375,824. This trade represents a 1.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Emily M. Leproust sold 1,730 shares of the stock in a transaction dated Friday, September 20th. The shares were sold at an average price of $46.94, for a total transaction of $81,206.20. Following the completion of the transaction, the chief executive officer now directly owns 495,523 shares of the company’s stock, valued at approximately $23,259,849.62. This trade represents a 0.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 98,118 shares of company stock valued at $4,391,151 over the last ninety days. Corporate insiders own 3.92% of the company’s stock.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.